Human anti-α-enolase antibody in sera from patients with Behçet's disease and rheumatologic disorders

JuHee Lee, Sung Bin Cho, Dongsik Bang, SangHo Oh, Keun Jae Ahn, Jihyun Kim, YongBeom Park, Soo Kon Lee, Kwanghoon Lee

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective. α-Enolase is a target antigen of IgM-type anti-endothelial cell antibody in patients with Behçet's disease (BD). The objective of this study was to assess the reactivity of serum anti-a-enolase antibodies in BD and in other rheumatologic diseases, and to evaluate the clinical significance of serum anti-a-enolase antibodies in BD. Methods. Enzyme-linked immunosorbent assay (ELISA) and immunoblotting were used to examine serum samples from patients with BD (n=100), systemic lupus erythematosus (SLE) (n=50), systemic sclerosis (n=21), rheumatoid arthritis (RA) (n=20), Takayasu's arteritis (n=20), dermatomyositis (n=17), mixed connective tissue disease (MCTD) (n=11), and samples from healthy volunteer donors (n=23). The medical records of patients with BD were reviewed to investigate their clinical characteristics. Results. Specific positive signals against recombinant human α-enolase were detected by IgM ELISA of serum samples from 56 of the 100 BD patients (56.0%), 24 of the 50 SLE patients (48.0%), 15 of the 21 systemic sclerosis patients (71.4%), 13 of the 20 RA patients (65.0%), 10 of the 20 Takayasu's arteritis patients (50.0%), 9 of the 17 dermatomyositis patients (52.9%), and 5 of the 11 MCTD patients (45.5%). The number of BD patients with vascular lesions was significantly higher in the anti-α-enolase antibody positive group than in the negative group (p=0.027). Conclusions. We demonstrated the reactivities of serum anti-α-enolase antibodies in BD and other rheumatologic diseases with moderate specificity and also found that serum anti-α-enolase antibodies in BD can be associated with vascular system involvement.

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume27
Issue number2 SUPPL.53
Publication statusPublished - 2009 Oct 26

Fingerprint

Phosphopyruvate Hydratase
Anti-Idiotypic Antibodies
Serum
Mixed Connective Tissue Disease
Takayasu Arteritis
Dermatomyositis
Systemic Scleroderma
Systemic Lupus Erythematosus
Immunoglobulin M
Blood Vessels
Rheumatoid Arthritis
Enzyme-Linked Immunosorbent Assay
Antibodies
Immunoblotting
Medical Records
Healthy Volunteers
Tissue Donors
Antigens

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

@article{88e78c9dbbd747e7a238a2fdb2800494,
title = "Human anti-α-enolase antibody in sera from patients with Beh{\cc}et's disease and rheumatologic disorders",
abstract = "Objective. α-Enolase is a target antigen of IgM-type anti-endothelial cell antibody in patients with Beh{\cc}et's disease (BD). The objective of this study was to assess the reactivity of serum anti-a-enolase antibodies in BD and in other rheumatologic diseases, and to evaluate the clinical significance of serum anti-a-enolase antibodies in BD. Methods. Enzyme-linked immunosorbent assay (ELISA) and immunoblotting were used to examine serum samples from patients with BD (n=100), systemic lupus erythematosus (SLE) (n=50), systemic sclerosis (n=21), rheumatoid arthritis (RA) (n=20), Takayasu's arteritis (n=20), dermatomyositis (n=17), mixed connective tissue disease (MCTD) (n=11), and samples from healthy volunteer donors (n=23). The medical records of patients with BD were reviewed to investigate their clinical characteristics. Results. Specific positive signals against recombinant human α-enolase were detected by IgM ELISA of serum samples from 56 of the 100 BD patients (56.0{\%}), 24 of the 50 SLE patients (48.0{\%}), 15 of the 21 systemic sclerosis patients (71.4{\%}), 13 of the 20 RA patients (65.0{\%}), 10 of the 20 Takayasu's arteritis patients (50.0{\%}), 9 of the 17 dermatomyositis patients (52.9{\%}), and 5 of the 11 MCTD patients (45.5{\%}). The number of BD patients with vascular lesions was significantly higher in the anti-α-enolase antibody positive group than in the negative group (p=0.027). Conclusions. We demonstrated the reactivities of serum anti-α-enolase antibodies in BD and other rheumatologic diseases with moderate specificity and also found that serum anti-α-enolase antibodies in BD can be associated with vascular system involvement.",
author = "JuHee Lee and Cho, {Sung Bin} and Dongsik Bang and SangHo Oh and Ahn, {Keun Jae} and Jihyun Kim and YongBeom Park and Lee, {Soo Kon} and Kwanghoon Lee",
year = "2009",
month = "10",
day = "26",
language = "English",
volume = "27",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "2 SUPPL.53",

}

Human anti-α-enolase antibody in sera from patients with Behçet's disease and rheumatologic disorders. / Lee, JuHee; Cho, Sung Bin; Bang, Dongsik; Oh, SangHo; Ahn, Keun Jae; Kim, Jihyun; Park, YongBeom; Lee, Soo Kon; Lee, Kwanghoon.

In: Clinical and Experimental Rheumatology, Vol. 27, No. 2 SUPPL.53, 26.10.2009.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Human anti-α-enolase antibody in sera from patients with Behçet's disease and rheumatologic disorders

AU - Lee, JuHee

AU - Cho, Sung Bin

AU - Bang, Dongsik

AU - Oh, SangHo

AU - Ahn, Keun Jae

AU - Kim, Jihyun

AU - Park, YongBeom

AU - Lee, Soo Kon

AU - Lee, Kwanghoon

PY - 2009/10/26

Y1 - 2009/10/26

N2 - Objective. α-Enolase is a target antigen of IgM-type anti-endothelial cell antibody in patients with Behçet's disease (BD). The objective of this study was to assess the reactivity of serum anti-a-enolase antibodies in BD and in other rheumatologic diseases, and to evaluate the clinical significance of serum anti-a-enolase antibodies in BD. Methods. Enzyme-linked immunosorbent assay (ELISA) and immunoblotting were used to examine serum samples from patients with BD (n=100), systemic lupus erythematosus (SLE) (n=50), systemic sclerosis (n=21), rheumatoid arthritis (RA) (n=20), Takayasu's arteritis (n=20), dermatomyositis (n=17), mixed connective tissue disease (MCTD) (n=11), and samples from healthy volunteer donors (n=23). The medical records of patients with BD were reviewed to investigate their clinical characteristics. Results. Specific positive signals against recombinant human α-enolase were detected by IgM ELISA of serum samples from 56 of the 100 BD patients (56.0%), 24 of the 50 SLE patients (48.0%), 15 of the 21 systemic sclerosis patients (71.4%), 13 of the 20 RA patients (65.0%), 10 of the 20 Takayasu's arteritis patients (50.0%), 9 of the 17 dermatomyositis patients (52.9%), and 5 of the 11 MCTD patients (45.5%). The number of BD patients with vascular lesions was significantly higher in the anti-α-enolase antibody positive group than in the negative group (p=0.027). Conclusions. We demonstrated the reactivities of serum anti-α-enolase antibodies in BD and other rheumatologic diseases with moderate specificity and also found that serum anti-α-enolase antibodies in BD can be associated with vascular system involvement.

AB - Objective. α-Enolase is a target antigen of IgM-type anti-endothelial cell antibody in patients with Behçet's disease (BD). The objective of this study was to assess the reactivity of serum anti-a-enolase antibodies in BD and in other rheumatologic diseases, and to evaluate the clinical significance of serum anti-a-enolase antibodies in BD. Methods. Enzyme-linked immunosorbent assay (ELISA) and immunoblotting were used to examine serum samples from patients with BD (n=100), systemic lupus erythematosus (SLE) (n=50), systemic sclerosis (n=21), rheumatoid arthritis (RA) (n=20), Takayasu's arteritis (n=20), dermatomyositis (n=17), mixed connective tissue disease (MCTD) (n=11), and samples from healthy volunteer donors (n=23). The medical records of patients with BD were reviewed to investigate their clinical characteristics. Results. Specific positive signals against recombinant human α-enolase were detected by IgM ELISA of serum samples from 56 of the 100 BD patients (56.0%), 24 of the 50 SLE patients (48.0%), 15 of the 21 systemic sclerosis patients (71.4%), 13 of the 20 RA patients (65.0%), 10 of the 20 Takayasu's arteritis patients (50.0%), 9 of the 17 dermatomyositis patients (52.9%), and 5 of the 11 MCTD patients (45.5%). The number of BD patients with vascular lesions was significantly higher in the anti-α-enolase antibody positive group than in the negative group (p=0.027). Conclusions. We demonstrated the reactivities of serum anti-α-enolase antibodies in BD and other rheumatologic diseases with moderate specificity and also found that serum anti-α-enolase antibodies in BD can be associated with vascular system involvement.

UR - http://www.scopus.com/inward/record.url?scp=70350157739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350157739&partnerID=8YFLogxK

M3 - Article

VL - 27

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 2 SUPPL.53

ER -